Polymorphs and pharmacokinetics of an antipsychotic drug candidate
Chao Hao,Yin Chen,Jiaying Xiong,Zhengge Yang,Lanchang Gao,Bi-Feng Liu,Xin Liu,Jian Jin,Guisen Zhang
DOI: https://doi.org/10.1016/j.ijpharm.2020.119600
IF: 6.51
2020-08-01
International Journal of Pharmaceutics
Abstract:<p>A potent antipsychotic drug candidate, 7-(4-(4-(6-fluorobenzo[<em>d</em>]-isoxazol-3-yl)-piperidin-1-yl)butoxy)-4-methyl-8-chloro -2H-chromen-2-one mesylate(CY611), with good in vitro and in vivo antipsychotic effects was investigated for preformulation evaluation by crystallography methods. Three anhydrous polymorphs(Form I–III), a monohydrate(Form IV), and a NMP solvate(Form V) were discovered and characterized by powder X-ray diffraction, thermal analysis, attenuated total reflection-fourier transform infrared spectroscopy and scanning electron microscopy. Form I, monohydrate Form IV, and a NMP solvate Form V of the drug candidate were isolated, and their structures were determined by single crystal X-ray diffraction. IDR and relative stability experiment were performed. Although Form II has the fastest release rate in water, it easy transformed to monohydrate which has the lowest release rate. In vivo pharmacokinetic study showed that the Form III has the highest bioavailability at 35.4%. Considering the balance between the physicochemical properties, bioavailability and manufacturability of the available polymorphs, Form III may be the optimal form candidate for the eventual formulation.</p>
pharmacology & pharmacy